Preclinical Studies of Novel Targeted Therapies

Hematology/Oncology Clinics of North America

Volumn 21, Issue 6, 2007, Pages 1071-1091

  Hideshima, Teru ^a   Anderson, Kenneth C ^a  

^a DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 PHENYLSULFAMOYLCINNAMOHYDROXAMIC ACID; 4 [4 (4' CHLORO 2 BIPHENYLYLMETHYL) 1 PIPERAZINYL] N [4 [3 DIMETHYLAMINO 1 (PHENYLTHIOMETHYL)PROPYLAMINO] 3 NITROBENZENESULFONYL]BENZAMIDE; 4 [N (2 HYDROXYETHYL) N [2 (3 INDOLYL)ETHYL]AMINOMETHYL]CINNAMOHYDROXAMIC ACID; ANSAMYCIN DERIVATIVE; ARRY 142886; AZD 6244; BORTEZOMIB; CD20 ANTIGEN; CD40 LIGAND; DEPSIPEPTIDE; DEXAMETHASONE; FIBROBLAST GROWTH FACTOR; FR 901228; GELDANAMYCIN; HEAT SHOCK PROTEIN 90; HEAT SHOCK PROTEIN 90 INHIBITOR; HISTONE DEACETYLASE INHIBITOR; HYDROXAMIC ACID DERIVATIVE; INTERLEUKIN 4; IPI 504; KD 5170; LBH 589; LENALIDOMIDE; MAMMALIAN TARGET OF RAPAMYCIN; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; NPI 0052; OBLIMERSEN; PERIFOSINE; PR 171; PROTEASOME INHIBITOR; PROTEIN KINASE B; RAPAMYCIN; TEMSIROLIMUS; TUBACIN; UNCLASSIFIED DRUG; VORINOSTAT; WNT1 PROTEIN;

BONE MARROW; HUMAN; MICROENVIRONMENT; MULTIPLE MYELOMA; NONHUMAN; PRIORITY JOURNAL; PROTEIN TARGETING; REVIEW;

BONE MARROW CELLS; CELL COMMUNICATION; DRUG EVALUATION, PRECLINICAL; HUMANS; IMMUNOLOGIC FACTORS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; MULTIPLE MYELOMA; PROTEASOME ENDOPEPTIDASE COMPLEX; STROMAL CELLS;

EID: 35748939416     PISSN: 08898588     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.hoc.2007.08.013     Document Type: Review

References (150)

1. Hideshima T., and Anderson K.C. Molecular mechanisms of novel therapeutic approaches for multiple myeloma. Nat Rev Cancer 2 (2002) 927-937
2. Hideshima T., Bergsagel P.L., Kuehl W.M., et al. Advances in biology of multiple myeloma: clinical applications. Blood 104 (2004) 607-618
3. Hideshima T., Mitsiades C., Tonon G., et al. Understanding multiple myeloma pathogenesis in the bone marrow to identify new therapeutic targets. Nat Rev Cancer 7 (2007) 585-598
4. Chauhan D., Kharbanda S., Ogata A., et al. Oncostatin M induces association of Grb2 with Janus kinase JAK2 in multiple myeloma cells. J Exp Med 182 (1995) 1801-1806
5. Costes V., Portier M., Lu Z.Y., et al. Interleukin-1 in multiple myeloma: producer cells and their role in the control of IL-6 production. Br J Haematol 103 (1998) 1152-1160
6. Lust J.A., and Donovan K.A. The role of interleukin-1 beta in the pathogenesis of multiple myeloma. Hematol Oncol Clin North Am 13 (1999) 1117-1125
7. Uchiyama H., Barut B.A., Mohrbacher A.F., et al. Adhesion of human myeloma-derived cell lines to bone marrow stromal cells stimulates IL-6 secretion. Blood 82 (1993) 3712-3720
8. Chauhan D., Uchiyama H., Akbarali Y., et al. Multiple myeloma cell adhesion-induced interleukin-6 expression in bone marrow stromal cells involves activation of NF-kB. Blood 87 (1996) 1104-1112
9. Urashima M., Ogata A., Chauhan D., et al. Transforming growth factor b1: Differential effects on multiple myeloma versus normal B cells. Blood 87 (1996) 1928-1938
10. Dankbar B., Padro T., Leo R., et al. Vascular endothelial growth factor and interleukin-6 in paracrine tumor-stromal cell interactions in multiple myeloma. Blood 95 (2000) 2630-2636
11. Gupta D., Treon S.P., Shima Y., et al. Adherence of multiple myeloma cells to bone marrow stromal cells upregulates vascular endothelial growth factor secretion: therapeutic applications. Leukemia 15 (2001) 1950-1961
12. Ogata A., Chauhan D., Teoh G., et al. Interleukin-6 triggers cell growth via the ras-dependent mitogen-activated protein kinase cascade. J Immunol 159 (1997) 2212-2221
13. Ogata A., Chauhan D., Urashima M., et al. Blockade of mitogen-activated protein kinase cascade signaling in interleukin-6 independent multiple myeloma cells. Clin Cancer Res 3 (1997) 1017-1022
14. Tai Y.T., Fulciniti M., Hideshima T., et al. Targeting MEK induces myeloma cell cytotoxicity and inhibits osteoclastogenesis. Blood 110 (2007) 1656-1663
15. Catlett-Falcone R., Landowski T.H., Oshiro M.M., et al. Constitutive activation of STAT-3 signaling confers resistance to apoptosis in human U266 myeloma cells. Immunity 10 (1999) 105-115
16. Puthier D., Bataille R., and Amiot M. IL-6 up-regulates mcl-1 in human myeloma cells through JAK/STAT rather than ras/MAP kinase pathway. Eur J Immunol 29 (1999) 3945-3950
17. Epling-Burnette P.K., Liu J.H., Catlett-Falcone R., et al. Inhibition of STAT3 signaling leads to apoptosis of leukemic large granular lymphocytes and decreased Mcl-1 expression. J Clin Invest 107 (2001) 351-362
18. Chauhan D., Pandey P., Ogata A., et al. Cytochrome-c dependent and independent induction of apoptosis in multiple myeloma cells. J Biol Chem 272 (1997) 29995-29997
19. Chauhan D., Hideshima T., Rosen S., et al. Apaf-1/cytochrome c independent and Smac dependent induction of apoptosis in multiple myeloma cells. J Biol Chem 276 (2001) 24453-24456
20. Hideshima T., Nakamura N., Chauhan D., et al. Biologic sequelae of interleukin-6 induced PI3-K/Akt signaling in multiple myeloma. Oncogene 20 (2001) 5991-6000
21. Chauhan D., Auclair D., Robinson E.K., et al. Identification of genes regulated by dexamethasone in multiple myeloma cells using oligonucleotide arrays. Oncogene 21 (2002) 1346-1358
22. Chauhan D., Li G., Auclair D., et al. Identification of genes regulated by 2-methoxyestradiol (2ME2) in multiple myeloma cells using oligonucleotide arrays. Blood 101 (2003) 3606-3614
23. Iwakoshi N.N., Lee A.H., Vallabhajosyula P., et al. Plasma cell differentiation and the unfolded protein response intersect at the transcription factor XBP-1. Nat Immunol 4 (2003) 321-329
24. Carrasco D.R., Sukhdeo K., Protopopov M., et al. The differentiation and stress response factor XBP-1 drives multiple myeloma pathogenesis. Cancer Cell 11 (2007) 349-360
25. Pulkki K., Pelliniemi T.T., Rajamaki A., et al. Soluble interleukin-6 receptor as a prognostic factor in multiple myeloma. Br J Haematol 92 (1996) 370-374
26. Kyrtsonis M.C., Dedoussis G., Zervas C., et al. Soluble interleukin-6 receptor (sIL-6R), a new prognostic factor in multiple myeloma. Br J Haematol 93 (1996) 398-400
27. Stasi R., Brunetti M., Parma A., et al. The prognostic value of soluble interleukin-6 receptor in patients with multiple myeloma. Cancer 82 (1998) 1860-1866
28. Tricot G., Spencer T., Sawyer J., et al. Predicting long-term (≥ 5 years) event-free survival in multiple myeloma patients following planned tandem autotransplants. Br J Haematol 116 (2002) 211-217
29. Tassone P., Galea E., Forciniti S., et al. The IL-6 receptor super-antagonist Sant7 enhances antiproliferative and apoptotic effects induced by dexamethasone and zoledronic acid on multiple myeloma cells. Int J Oncol 21 (2002) 867-873
30. Tassone P., Neri P., Burger R., et al. Combination therapy with IL-6 receptor super-antagonist Sant7 and dexamethasone induces antitumor effects in a novel SCID-hu in vivo model of human multiple myeloma. Clin Cancer Res 11 (2005) 4251-4258
31. Mitsiades C.S., Mitsiades N.S., McMullan C.J., et al. Inhibition of the insulin-like growth factor receptor-1 tyrosine kinase activity as a therapeutic strategy for multiple myeloma, other hematologic malignancies, and solid tumors. Cancer Cell 5 (2004) 221-230
32. Pollak M.N. Insulin-like growth factors and neoplasia. Novartis Found Symp 262 (2004) 84-98
33. Standal T., Borset M., Lenhoff S., et al. Serum insulinlike growth factor is not elevated in patients with multiple myeloma but is still a prognostic factor. Blood 100 (2002) 3925-3929
34. Jelinek D.F., Witzig T.E., and Arendt B.K. A role for insulin-like growth factor in the regulation of IL-6-responsive human myeloma cell line growth. J Immunol 159 (1997) 487-496
35. Qiang Y.W., Kopantzev E., and Rudikoff S. Insulinlike growth factor-I signaling in multiple myeloma: downstream elements, functional correlates, and pathway cross-talk. Blood 99 (2002) 4138-4146
36. Mitsiades C.S., Mitsiades N., Poulaki V., et al. Activation of NF-kB and upregulation of intracellular anti-apoptotic proteins via the IGF-1/Akt signaling in human multiple myeloma cells: therapeutic implications. Oncogene 21 (2002) 5673-5683
37. Mitsiades C.S., Mitsiades N., Kung A.L., et al. The IGF/IGF-1R system is a major therapeutic target for multiple myeloma, other hematologic malignancies and solid tumors. Blood 100 (2002) 170a
38. Tai Y.T., Podar K., Catley L., et al. Insulin-like growth factor-1 induces adhesion and migration in human multiple myeloma cells via activation of beta1-integrin and phosphatidylinositol 3'-kinase/AKT signaling. Cancer Res 63 (2003) 5850-5858
39. Podar K., Tai Y.T., Cole C.E., et al. Essential role of caveolae in interleukin-6- and insulin-like growth factor I-triggered Akt-1-mediated survival of multiple myeloma cells. J Biol Chem 278 (2003) 5794-5801
40. Mitsiades C.S., Mitsiades N., Munshi N.C., et al. Focus on multiple myeloma. Cancer Cell 6 (2004) 439-444
41. Podar K., and Anderson K.C. The pathophysiological role of VEGF in hematological malignancies: therapeutic implications. Blood 105 (2005) 1383-1395
42. Podar K., Tai Y.T., Davies F.E., et al. Vascular endothelial growth factor triggers signaling cascades mediating multiple myeloma cell growth and migration. Blood 98 (2001) 428-435
43. Podar K., Tai Y.T., Lin B.K., et al. Vascular endothelial growth factor-induced migration of multiple myeloma cells is associated with beta 1 integrin- and phosphatidylinositol 3-kinase-dependent PKC alpha activation. J Biol Chem 277 (2002) 7875-7881
44. Lin B., Podar K., Gupta D., et al. The vascular endothelial growth factor receptor tyrosine kinase inhibitor PTK787/ZK222584 inhibits growth and migration of multiple myeloma cells in the bone marrow microenvironment. Cancer Res 62 (2002) 5019-5026
45. Podar K., Catley L.P., Tai Y.T., et al. GW654652, the pan-inhibitor of VEGF receptors, blocks the growth and migration of multiple myeloma cells in the bone marrow microenvironment. Blood 103 (2004) 3474-3479
46. Podar K., Shringarpure R., Tai Y.T., et al. Caveolin-1 is required for vascular endothelial growth factor-triggered multiple myeloma cell migration and is targeted by bortezomib. Cancer Res 64 (2004) 7500-7506
47. Le Gouill S., Podar K., Amiot M., et al. VEGF induces MCL-1 upregulation and protects multiple myeloma cells against apoptosis. Blood 104 (2004) 2886-2892
48. Podar K., Tonon G., Sattler M., et al. The small-molecule VEGF receptor inhibitor pazopanib (GW786034B) targets both tumor and endothelial cells in multiple myeloma. Proc Natl Acad Sci U S A 103 (2006) 19478-19483
49. Vacca A., Ribatti D., Presta M., et al. Bone marrow neovascularization, plasma cell angiogenic potential, and matrix metalloproteinase-2 secretion parallel progression of human multiple myeloma. Blood 93 (1999) 3064-3073
50. Bisping G., Leo R., Wenning D., et al. Paracrine interactions of basic fibroblast growth factor and interleukin-6 in multiple myeloma. Blood 101 (2003) 2775-2783
51. Chesi M., Nardini E., Lim R.S.C., et al. The t(4;14) translocation in myeloma dysregulates both FGFR3 and a novel gene, MMSET, resulting in IgH/MMSET hybrid transcripts. Blood 92 (1998) 3025-3034
52. Chesi M., Nardini E., Brents L.A., et al. Frequent translocation t(4;14)(p16.3;q32.3) in multiple myeloma: association with increased expression and activating mutations of fibroblast growth factor receptor 3. Nat Genet 16 (1997) 260-264
53. Keats J.J., Reiman T., Maxwell C.A., et al. In multiple myeloma, t(4;14)(p16;q32) is an adverse prognostic factor irrespective of FGFR3 expression. Blood 101 (2003) 1520-1529
54. Chang H., Stewart A.K., Qi X.Y., et al. Immunohistochemistry accurately predicts FGFR3 aberrant expression and t(4;14) in multiple myeloma. Blood 106 (2005) 353-355
55. Trudel S., Li Z.H., Wei E., et al. CHIR-258, a novel, multitargeted tyrosine kinase inhibitor for the potential treatment of t(4;14) multiple myeloma. Blood 105 (2005) 2941-2948
56. Trudel S., Stewart A.K., Rom E., et al. The inhibitory anti-FGFR3 antibody, PRO-001, is cytotoxic to t(4;14) multiple myeloma cells. Blood 107 (2006) 4039-4046
57. Trudel S., Ely S., Farooqi Y., et al. Inhibition of fibroblast growth factor receptor 3 induces differentiation and apoptosis in t(4;14) myeloma. Blood 103 (2004) 3521-3528
58. Chen J., Lee B.H., Williams I.R., et al. FGFR3 as a therapeutic target of the small molecule inhibitor PKC412 in hematopoietic malignancies. Oncogene 24 (2005) 8259-8267
59. Moreaux J., Legouffe E., Jourdan E., et al. BAFF and APRIL protect myeloma cells from apoptosis induced by interleukin 6 deprivation and dexamethasone. Blood 103 (2004) 3148-3157
60. Novak A.J., Darce J.R., Arendt B.K., et al. Expression of BCMA, TACI, and BAFF-R in multiple myeloma: a mechanism for growth and survival. Blood 103 (2004) 689-694
61. Tai Y.T., Li X.F., Breitkreutz I., et al. Role of B-cell-activating factor in adhesion and growth of human multiple myeloma cells in the bone marrow microenvironment. Cancer Res 66 (2006) 6675-6682
62. Derksen P.W., Tjin E., Meijer H.P., et al. Illegitimate WNT signaling promotes proliferation of multiple myeloma cells. Proc Natl Acad Sci U S A 101 (2004) 6122-6127
63. Sukhdeo K., Mani M., Zhang Y., et al. Targeting the beta-catenin/TCF transcriptional complex in the treatment of multiple myeloma. Proc Natl Acad Sci U S A 104 (2007) 7516-7521
64. Niida A., Hiroko T., Kasai M., et al. DKK1, a negative regulator of Wnt signaling, is a target of the beta-catenin/TCF pathway. Oncogene 23 (2004) 8520-8526
65. Tian E., Zhan F., Walker R., et al. The role of the Wnt-signaling antagonist DKK1 in the development of osteolytic lesions in multiple myeloma. N Engl J Med 349 (2003) 2483-2494
66. Yaccoby S., Ling W., Zhan F., et al. Antibody-based inhibition of DKK1 suppresses tumor-induced bone resorption and multiple myeloma growth in vivo. Blood 109 (2007) 2106-2111
67. Tai Y.T., Podar K., Gupta D., et al. CD40 activation induces p53-dependent vascular endothelial growth factor secretion in human multiple myeloma cells. Blood 99 (2002) 1419-1427
68. Tai Y.T., Podar K., Mitsiades N., et al. CD40 induces human multiple myeloma cell migration via phosphatidylinositol 3-kinase/AKT/NF-kappa B signaling. Blood 101 (2003) 2762-2769
69. Tai Y.T., Catley L.P., Mitsiades C.S., et al. Mechanisms by which SGN-40, a humanized anti-CD40 antibody, induces cytotoxicity in human multiple myeloma cells: clinical implications. Cancer Res 64 (2004) 2846-2852
70. Hayashi T., Hideshima T., Akiyama M., et al. Molecular mechanisms whereby immunomodulatory drugs activate natural killer cells: clinical application. Br J Haematol 128 (2005) 192-203
71. Tai Y.T., Li X.F., Catley L., et al. Immunomodulatory drug lenalidomide (CC-5013, IMiD3) augments anti-CD40 SGN-40-induced cytotoxicity in human multiple myeloma: clinical implications. Cancer Res 65 (2005) 11712-11720
72. Treon S.P., Pilarski L.M., Belch A.R., et al. CD20-directed serotherapy in patients with multiple myeloma: biologic considerations and therapeutic applications. J Immunother 25 (2002) 72-81
73. Tai Y.-T., Song W., Li X.-F., et al. Killing of drug-sensitive and resistant myeloma cells and disruption of their bone marrow stromal interaction by HuLuc63, a novel humanized anti-CS1 monoclonal antibody. Blood 108 (2006) 990a
74. Berkers C.R., Verdoes M., Lichtman E., et al. Activity probe for in vivo profiling of the specificity of proteasome inhibitor bortezomib. Nat Methods 2 (2005) 357-362
75. Baldwin Jr. A.S. The NF-kB and I kB proteins: new discoveries and insights. Annu Rev Immunol 14 (1996) 649-683
76. Beg A.A., and Baldwin Jr. A.S. The IkB proteins: multifunctional regulators of Rel NF-kB transcription factors. Genes Dev 7 (1993) 2064-2070
77. Zandi E., Chen Y., and Karin M. Direct phosphorylation of IkappaB by IKKalpha and IKKbeta: discrimination between free and NF-kappaB-bound substrate. Science 281 (1998) 1360-1363
78. Zandi E., Rothwarf D.M., Delhase M., et al. The IkB kinase complex (IKK) contains two kinase subunits, IKKa and IKKb, necessary for IkB phosphorylation and NF-kB activation. Cell 91 (1997) 243-252
79. Hideshima T., Richardson P., Chauhan D., et al. The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells. Cancer Res 61 (2001) 3071-3076
80. Mitsiades N., Mitsiades C.S., Poulaki V., et al. Molecular sequelae of proteasome inhibition in human multiple myeloma cells. Proc Natl Acad Sci U S A 99 (2002) 14374-14379
81. Mitsiades N., Mitsiades C.S., Richardson P.G., et al. The proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: therapeutic applications. Blood 101 (2003) 2377-2380
82. Hideshima T., Mitsiades C., Akiyama M., et al. Molecular mechanisms mediating antimyeloma activity of proteasome inhibitor PS-341. Blood 101 (2003) 1530-1534
83. Lee A.H., Iwakoshi N.N., Anderson K.C., et al. Proteasome inhibitors disrupt the unfolded protein response in myeloma cells. Proc Natl Acad Sci U S A 100 (2003) 9946-9951
84. Hideshima T., Chauhan D., Hayashi T., et al. Proteasome inhibitor PS-341 abrogates IL-6 triggered signaling cascades via caspase-dependent downregulation of gp130 in multiple myeloma. Oncogene 22 (2003) 8386-8393
85. Hideshima T., Chauhan D., Schlossman R.L., et al. Role of TNF-a in the pathophysiology of human multiple myeloma: therapeutic applications. Oncogene 20 (2001) 4519-4527
86. Hideshima T., Chauhan D., Richardson P., et al. NF-kB as a therapeutic target in multiple myeloma. J Biol Chem 277 (2002) 16639-16647
87. Heider U., Kaiser M., Muller C., et al. Bortezomib increases osteoblast activity in myeloma patients irrespective of response to treatment. Eur J Haematol 77 (2006) 233-238
88. Giuliani N., Morandi F., Tagliaferri S., et al. The proteasome inhibitor bortezomib affects osteoblast differentiation in vitro and in vivo in multiple myeloma patients. Blood 110 (2007) 334-338
89. von Metzler I., Krebbel H., Hecht M., et al. Bortezomib inhibits human osteoclastogenesis. Leukemia 21 (2007) 2025-2034
90. Chauhan D., Catley L., Li G., et al. A novel orally active proteasome inhibitor induces apoptosis in multiple myeloma cells with mechanisms distinct from Bortezomib. Cancer Cell 8 (2005) 407-419
91. Miller C.P., Ban K., Dujka M.E., et al. NPI-0052, a novel proteasome inhibitor, induces caspase-8 and ROS-dependent apoptosis alone and in combination with HDAC inhibitors in leukemia cells. Blood 110 (2007) 267-277
92. Demo S.D., Kirk C.J., Aujay M.A., et al. Antitumor activity of PR-171, a novel irreversible inhibitor of the proteasome. Cancer Res 67 (2007) 6383-6391
93. O'Connor O.A., Orlowski R.Z., Alsina M., et al. Multicenter phase I studies to evaluate the safety, tolerability, and clinical response to intensive dosing with the proteasome Inhibitor PR-171 in patients with relapsed or refractory hematological malignancies. Blood 108 (2006) 687a
94. Hideshima T., Chauhan D., Shima Y., et al. Thalidomide and its analogues overcome drug resistance of human multiple myeloma cells to conventional therapy. Blood 96 (2000) 2943-2950
95. LeBlanc R., Hideshima T., Catley L.P., et al. Immunomodulatory drug costimulates T cells via the B7-CD28 pathway. Blood 103 (2004) 1787-1790
96. Davies F.E., Raje N., Hideshima T., et al. Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma. Blood 98 (2001) 210-216
97. Bolden J.E., Peart M.J., and Johnstone R.W. Anticancer activities of histone deacetylase inhibitors. Nat Rev Drug Discov 5 (2006) 769-784
98. Finnin M.S., Donigian J.R., Cohen A., et al. Structures of a histone deacetylase homologue bound to the TSA and SAHA inhibitors. Nature 401 (1999) 188-193
99. Marks P.A., and Jiang X. Histone deacetylase inhibitors in programmed cell death and cancer therapy. Cell Cycle 4 (2005) 549-551
100. Marks P.A., and Dokmanovic M. Histone deacetylase inhibitors: discovery and development as anticancer agents. Expert Opin Investig Drugs 14 (2005) 1497-1511
101. Lin R.J., Nagy L., Inoue S., et al. Role of the histone deacetylase complex in acute promyelocytic leukaemia. Nature 391 (1998) 811-814
102. Marks P., Rifkind R.A., Richon V.M., et al. Histone deacetylases and cancer: causes and therapies. Nat Rev Cancer 1 (2001) 194-202
103. Mitsiades N., Mitsiades C.S., Richardson P.G., et al. Molecular sequelae of histone deacetylase inhibition in human malignant B cells. Blood 101 (2003) 4055-4062
104. Huang L., Sowa Y., Sakai T., et al. Activation of the p21WAF1/CIP1 promoter independent of p53 by the histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA) through the Sp1 sites. Oncogene 19 (2000) 5712-5719
105. Richon V.M., Sandhoff T.W., Rifkind R.A., et al. Histone deacetylase inhibitor selectively induces p21WAF1 expression and gene-associated histone acetylation. Proc Natl Acad Sci U S A 97 (2000) 10014-10019
106. Mitsiades C.S., Mitsiades N.S., McMullan C.J., et al. Transcriptional signature of histone deacetylase inhibition in multiple myeloma: biological and clinical implications. Proc Natl Acad Sci U S A 101 (2004) 540-545
107. Fandy T.E., Shankar S., Ross D.D., et al. Interactive effects of HDAC inhibitors and TRAIL on apoptosis are associated with changes in mitochondrial functions and expressions of cell cycle regulatory genes in multiple myeloma. Neoplasia 7 (2005) 646-657
108. Remiszewski S.W., Sambucetti L.C., Bair K.W., et al. N-hydroxy-3-phenyl-2-propenamides as novel inhibitors of human histone deacetylase with in vivo antitumor activity: discovery of (2E)-N-hydroxy-3-[4-[[(2-hydroxyethyl)[2-(1H-indol-3-yl)ethyl]amino]methyl]phenyl]-2-propenamide (NVP-LAQ824). J Med Chem 46 (2003) 4609-4624
109. Atadja P., Gao L., Kwon P., et al. Selective growth inhibition of tumor cells by a novel histone deacetylase inhibitor, NVP-LAQ824. Cancer Res 64 (2004) 689-695
110. Fiskus W., Pranpat M., Balasis M., et al. Histone deacetylase inhibitors deplete enhancer of zeste 2 and associated polycomb repressive complex 2 proteins in human acute leukemia cells. Mol Cancer Ther 5 (2006) 3096-3104
111. Guo F., Sigua C., Tao J., et al. Cotreatment with histone deacetylase inhibitor LAQ824 enhances Apo-2L/tumor necrosis factor-related apoptosis inducing ligand-induced death inducing signaling complex activity and apoptosis of human acute leukemia cells. Cancer Res 64 (2004) 2580-2589
112. Rosato R.R., Maggio S.C., Almenara J.A., et al. The histone deacetylase inhibitor LAQ824 induces human leukemia cell death through a process involving XIAP down-regulation, oxidative injury, and the acid sphingomyelinase-dependent generation of ceramide. Mol Pharmacol 69 (2006) 216-225
113. Weisberg E., Catley L., Kujawa J., et al. Histone deacetylase inhibitor NVP-LAQ824 has significant activity against myeloid leukemia cells in vitro and in vivo. Leukemia 18 (2004) 1951-1963
114. Qian D.Z., Wang X., Kachhap S.K., et al. The histone deacetylase inhibitor NVP-LAQ824 inhibits angiogenesis and has a greater antitumor effect in combination with the vascular endothelial growth factor receptor tyrosine kinase inhibitor PTK787/ZK222584. Cancer Res 64 (2004) 6626-6634
115. Catley L., Weisberg E., Tai Y.T., et al. NVP-LAQ824 is a potent novel histone deacetylase inhibitor with significant activity against multiple myeloma. Blood 102 (2003) 2615-2622
116. George P., Bali P., Annavarapu S., et al. Combination of the histone deacetylase inhibitor LBH589 and the hsp90 inhibitor 17-AAG is highly active against human CML-BC cells and AML cells with activating mutation of FLT-3. Blood 105 (2005) 1768-1776
117. Fiskus W., Pranpat M., Bali P., et al. Combined effects of novel tyrosine kinase inhibitor AMN107 and histone deacetylase inhibitor LBH589 against Bcr-Abl-expressing human leukemia cells. Blood 108 (2006) 645-652
118. Geng L., Cuneo K.C., Fu A., et al. Histone deacetylase (HDAC) inhibitor LBH589 increases duration of gamma-H2AX foci and confines HDAC4 to the cytoplasm in irradiated non-small cell lung cancer. Cancer Res 66 (2006) 11298-11304
119. Yu C., Friday B.B., Lai J.P., et al. Abrogation of MAPK and Akt signaling by AEE788 synergistically potentiates histone deacetylase inhibitor-induced apoptosis through reactive oxygen species generation. Clin Cancer Res 13 (2007) 1140-1148
120. Qian D.Z., Kato Y., Shabbeer S., et al. Targeting tumor angiogenesis with histone deacetylase inhibitors: the hydroxamic acid derivative LBH589. Clin Cancer Res 12 (2006) 634-642
121. Maiso P., Carvajal-Vergara X., Ocio E.M., et al. The histone deacetylase inhibitor LBH589 is a potent antimyeloma agent that overcomes drug resistance. Cancer Res 66 (2006) 5781-5789
122. Catley L., Weisberg E., Kiziltepe T., et al. Aggresome induction by proteasome inhibitor bortezomib and alpha-tubulin hyperacetylation by tubulin deacetylase (TDAC) inhibitor LBH589 are synergistic in myeloma cells. Blood 108 (2006) 3441-3449
123. Haggarty S.J., Koeller K.M., Wong J.C., et al. Domain-selective small-molecule inhibitor of histone deacetylase 6 (HDAC6)-mediated tubulin deacetylation. Proc Natl Acad Sci U S A 100 (2003) 4389-4394
124. Garcia-Mata R., Gao Y.S., and Sztul E. Hassles with taking out the garbage: aggravating aggresomes. Traffic 3 (2002) 388-396
125. Kawaguchi Y., Kovacs J.J., McLaurin A., et al. The deacetylase HDAC6 regulates aggresome formation and cell viability in response to misfolded protein stress. Cell 115 (2003) 727-738
126. Hideshima H., Bradner J.E., Wong J., et al. Small molecule inhibition of proteasome and aggresome function induces synergistic anti-tumor activity in multiple myeloma. Proc Natl Acad Sci USA 102 (2005) 8567-8572
127. Furumai R., Matsuyama A., Kobashi N., et al. FK228 (depsipeptide) as a natural prodrug that inhibits class I histone deacetylases. Cancer Res 62 (2002) 4916-4921
128. Khan S.B., Maududi T., Barton K., et al. Analysis of histone deacetylase inhibitor, depsipeptide (FR901228), effect on multiple myeloma. Br J Haematol 125 (2004) 156-161
129. Plumb J.A., Finn P.W., Williams R.J., et al. Pharmacodynamic response and inhibition of growth of human tumor xenografts by the novel histone deacetylase inhibitor PXD101. Mol Cancer Ther 2 (2003) 721-728
130. Feng R., Hager J.H., Hassig C.A., et al. A novel, mercaptoketone-based HDAC inhibitor, KD5170 exerts marked inhibition of osteoclast formation and anti-Myeloma activity in vitro. Blood 108 (2006) 991a
131. Chatterjee M., Jain S., Stuhmer T., et al. STAT3 and MAPK signaling maintain overexpression of heat shock proteins 90alpha and beta in multiple myeloma cells, which critically contribute to tumor-cell survival. Blood 109 (2007) 720-728
132. Mitsiades C.S., Mitsiades N.S., McMullan C.J., et al. Antimyeloma activity of heat shock protein-90 inhibition. Blood 107 (2006) 1092-1100
133. Davenport E.L., Moore H.E., Dunlop A.S., et al. Heat shock protein inhibition is associated with activation of the unfolded protein response (UPR) pathway in myeloma plasma cells. Blood 110 (2007) 2641-2649
134. Sydor J.R., Normant E., Pien C.S., et al. Development of 17-allylamino-17-demethoxygeldanamycin hydroquinone hydrochloride (IPI-504), an anti-cancer agent directed against Hsp90. Proc Natl Acad Sci U S A 103 (2006) 17408-17413
135. Tu Y., Gardner A., and Lichtenstein A. The phosphatidylinositol 3-kinase/AKT kinase pathway in multiple myeloma plasma cells: roles in cytokine-dependent survival and proliferative responses. Cancer Res 60 (2000) 6763-6770
136. Hideshima T., Catley L., Yasui H., et al. Perifosine, an oral bioactive novel alkylphospholipid, inhibits Akt and induces in vitro and in vivo cytotoxicity in human multiple myeloma cells. Blood 107 (2006) 4053-4062
137. Gajate C., and Mollinedo F. Edelfosine and perifosine induce selective apoptosis in multiple myeloma by recruitment of death receptors and downstream signaling molecules into lipid rafts. Blood 109 (2007) 711-719
138. Hideshima T., Catley L., Raje N., et al. Inhibition of Akt induces significant downregulation of survivin and cytotoxicity in human multiple myeloma cells. Br J Haematol 138 (2007) 783-791
139. Shi Y., Hsu J.H., Hu L., et al. Signal pathways involved in activation of p70S6K and phosphorylation of 4E-BP1 following exposure of multiple myeloma tumor cells to interleukin-6. J Biol Chem 277 (2002) 15712-15720
140. Pene F., Claessens Y.E., Muller O., et al. Role of the phosphatidylinositol 3-kinase/Akt and mTOR/P70S6-kinase pathways in the proliferation and apoptosis in multiple myeloma. Oncogene 21 (2002) 6587-6597
141. Stromberg T., Dimberg A., Hammarberg A., et al. Rapamycin sensitizes multiple myeloma cells to apoptosis induced by dexamethasone. Blood 103 (2004) 3138-3147
142. Shi Y., Gera J., Hu L., et al. Enhanced sensitivity of multiple myeloma cells containing PTEN mutations to CCI-779. Cancer Res 62 (2002) 5027-5034
143. Raje N., Kumar S., Hideshima T., et al. Combination of the mTOR inhibitor rapamycin and Revlimid™(CC-5013) has synergistic activity in multiple myeloma. Blood 104 (2004) 4188-4193
144. Frost P., Moatamed F., Hoang B., et al. In vivo antitumor effects of the mTOR inhibitor CCI-779 against human multiple myeloma cells in a xenograft model. Blood 104 (2004) 4181-4187
145. Frost P., Shi Y., Hoang B., et al. AKT activity regulates the ability of mTOR inhibitors to prevent angiogenesis and VEGF expression in multiple myeloma cells. Oncogene 26 (2007) 2255-2262
146. van de Donk N.W., de Weerdt O., Veth G., et al. G3139, a Bcl-2 antisense oligodeoxynucleotide, induces clinical responses in VAD refractory myeloma. Leukemia 18 (2004) 1078-1084
147. Badros A.Z., Goloubeva O., Rapoport A.P., et al. Phase II study of G3139, a Bcl-2 antisense oligonucleotide, in combination with dexamethasone and thalidomide in relapsed multiple myeloma patients. J Clin Oncol 23 (2005) 4089-4099
148. Kline M.P., Rajkumar S.V., Timm M.M., et al. ABT-737, an inhibitor of Bcl-2 family proteins, is a potent inducer of apoptosis in multiple myeloma cells. Leukemia 21 (2007) 1549-1560
149. Chauhan D., Velankar M., Brahmandam M., et al. A novel Bcl-2/Bcl-X(L)/Bcl-w inhibitor ABT-737 as therapy in multiple myeloma. Oncogene 26 (2007) 2374-2380
150. Trudel S., Stewart A.K., Li Z., et al. The Bcl-2 family protein inhibitor, ABT-737, has substantial antimyeloma activity and shows synergistic effect with dexamethasone and melphalan. Clin Cancer Res 13 (2007) 621-629